Loading clinical trials...
Loading clinical trials...
The purpose of the vaccination protocol is to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University Hospital Tuebingen
Collaborators
NCT07371663 · Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), and more
NCT06794775 · Malignant Melanoma Stage III
NCT01898039 · Malignant Melanoma
NCT06209580 · Malignant Melanoma, Advanced Solid Tumors
NCT05478876 · Malignant Melanoma, Gynecologic Cancer
Department of Dermatology, University of Tuebingen
Tübingen
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions